Anlotinib, as a novel oral small-molecule multi-target tyrosine kinase inhibitor, has been demonstrated to inhibit tumor growth and exert anti-tumor angiogenesis effects, effectively inhibiting PDGFR, C-KIT, FGFR, VEGFR, and other kinases that are critical to cancer progression (15, 16). Here, KDR is linked to neoplasm.